Ponesimod shows promise in relapsing MS
04 May 2021
byRoshini Claire Anthony
Ponesimod, a highly selective sphingosine-1-phosphate receptor 1 modulator, demonstrated superiority over teriflunomide in reducing relapse rate, fatigue, and active lesions in patients with relapsing multiple sclerosis (RMS), results of the phase III OPTIMUM* trial showed.